Clinical Study "Common" Name (formal title)	Number of enrollees	Funding source (pharmaceutical company/National Institutes of Health [NIH])	Year complete	Primary publication	Full study treatment protocol/patient disposition
TENAYA/LUCERNE (Efficacy, Durability, and Safety of Intravitreal Faricimab Up to Every 16 Weeks for Neovascular Age-Related Macular Degeneration (TENAYA and LUCERNE): Two Randomised, Double-Masked, Phase 3, Non-Inferiority Trials)	1329	TENAYA and LUCRNE: Hoffmann-LaRoche (TENAYA: NCT03823287) (LUCERNE: NCT03823300)	TENAYA: 2022 LUCERNE: 2023	Heier JS, et al. Lancet. 2022;399:729-740. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00010-1/fulltext